Stereoselective Synthesis of 4-O-Tosyltetrahydropyrans via Prins Cyclization Reaction of Enol Ethers

Sujit Sarkar
Namita Devi
Bikoshita Porashar
Santu Ruidas
Anil K Saikia*

Department of Chemistry, Indian Institute of Technology
Guwahati, Guwahati 781039, Assam, India
asaika@iitg.ac.in

Received: 20.01.2019
Accepted after revision: 05.02.2019
Published online: 28.02.2019
DOI: 10.1055/s-0037-1611679; Art ID: so-2018-d0065-op

License terms:

Abstract Intramolecular cyclization of enol ethers mediated by para-toluene sulfonic acid leads to substituted tetrahydropyrans in good to moderate yields. The reaction is diastereoselective.

Key words tosyl tetrahydropyrans, Prins reaction, enol ether, cyclization, heterocycle

Saturated six-membered cyclic ethers, better known as tetrahydropyrans (THPs), are ubiquitous in nature and represent useful precursors for the synthesis of many biologically active molecules.1 For example, neopeltolide 1 is a marine natural product isolated from Neopeltidae, collected from the north Jamaican coast. It inhibits cancer cell lines such as A-549 human lung adenocarcinoma, human ovarian sarcoma, and murine leukemia, with IC_{50} of 1.2, 5.1, and 0.56 nM, respectively. It also inhibits the growth of the fungal pathogen Candida albicans with an inhibitory concentration of 0.62 μg mL^{-1}.2 4-Hydroxytetrahydropyran-containing natural products, catechols 2 and 3, isolated from extracts of Plectranthus sylvestris (labiatae), a plant found in the woody hills in East Africa, are potent antioxidants and possess anti-inflammatory properties.3 Similarly, apicularen A 4, isolated from various strains of the myxobacterial genus Chondromyces and shows antiproliferative properties against cancer cell lines such as ovarian, prostate, lung, kidney, cervix, leukemia, and histiocytic cells with IC_{50} values 0.23–6.79 μM. It is a novel antiangiogenic agent and may suppress growth of tumors in a dose-dependent manner (Figure 1).4

Over the years, the 4-substituted tetrahydropyran rings have been constructed via Lewis or Brønsted acid catalyzed/mediated Prins reaction of homoallyl alcohols and aldehydes followed by trapping with various nucleophiles such as hydroxide,5 halide,6 aryl,7 tosyl,8 and nitrile9 groups. An earlier report has described the synthesis of 4-hydroxytetrahydropyrans via hydroxyl-Prins cyclization of homooly acryloyl ethers mediated by TFA and K_{2}CO_{3}.10 We have reported the stereoselective synthesis of dihydroxyprpyrins, tetrahydrofurans, and tetrahydrothiophenes via Prins reaction of homoallyl, homopropargyl alcohols and thiols.11 We have also studied the dual role of p-TSA as an activator as well as a nucleophile in the aza-Prins cyclization reaction.12 Based on our experience in Prins cyclization

Figure 1 Some biologically active tetrahydropyrans
reactions, we envisaged that p-TSA could act as a nucleophile and activator in a Prins cyclization reaction of acryloyl ethers. Herein, we wish to report a mild and efficient approach for the synthesis of 4-O-tosyl tetrahydropyran via Prins reaction of acryloyl enol ethers mediated by p-toluenesulfonic acid (p-TSA), which acts as an activator as well as a nucleophile.

Initially, we reacted (E)-ethyl 3-(but-3-en-1-yloxy)acrylate 5a with 1.2 equivalents of p-TSA acid in dichloromethane at reflux, and the reaction proceeded smoothly to afford ethyl 2-(((2R*,4S*)-4-(tosyloxy)tetrahydro-2H-pyran-2-yl)acetate (6a) in 68% yield as a mixture of 2,4,6-cis and 2,4- and 4,6-trans isomers in a ratio of 93:7, with the stereoisomer having the all-cis relationship being the major component. Catalytic amounts of p-TSA were found to be inefficient, and excess p-TSA (more than 1.2 equiv.) produced a mixture of products. It was also found that only CH2Cl2 is a suitable solvent; other polar protic solvents such as CH3OH, EtOH, CH3COOH and polar aprotic solvents such as CH3CN, THF, DMF, DMSO did not result in the desired product.

To investigate the substrate scope with these optimal reaction conditions, a variety of homoallyl acryloyl ethers was synthesized according to reported methods by Michael addition of homoallyl alcohols to ethyl propiolate using N-methyl morpholine (NMM) as a base in dichloromethane at ambient temperature. (Scheme 1).

These acryloyl enol ethers were subjected to p-TSA-mediated Prins cyclization; the results are shown in Table 1. Both aliphatic and aromatic substituted acryloyl ethers worked well and produced moderate to high yields of cyclized material with high diastereoselectivity. Substrates having aromatic substituents (entries 2–6, 9–12, 16) gave higher yields compared with aliphatic substrates (entries 8, 13–14 and 17). Substrates having aromatic substituents with highly electron-donating (entry 7) or electron-withdrawing groups (entry 15) did not furnish the desired products. This might be due to the interaction of the acid with methoxy13 and nitro14 groups of the aromatic aldehydes.

The reaction is highly diastereoselective, with a cis-relationship among the substituents on the tetrahydropyran ring. The diastereoselectivity was confirmed by 1H and 13C NMR spectroscopic analysis of the crude product, and the cis stereochemistry was determined based on NOE analysis of compound 6f. A strong NOE between hydrogen at C-2 and C-4 as well as interaction between C-2 and C-6 clearly suggests all substituents are in a cis relationship (Scheme 2).

Table 1 Synthesis of O-Tosylated Tetrahydropyran s via Prins Cyclization Reaction

<table>
<thead>
<tr>
<th>Entry</th>
<th>5</th>
<th>6</th>
<th>Ratio</th>
<th>Yield (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td>93:7</td>
<td>68</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td>93:7</td>
<td>74</td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td>99:1</td>
<td>79</td>
</tr>
</tbody>
</table>
Table 1 (continued)

<table>
<thead>
<tr>
<th>Entry</th>
<th>5</th>
<th>6</th>
<th>Ratio</th>
<th>Yield (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td><img src="image" alt="Structure 5d" /></td>
<td><img src="image" alt="Structure 6d" /></td>
<td>95:5</td>
<td>76</td>
</tr>
<tr>
<td>5</td>
<td><img src="image" alt="Structure 5e" /></td>
<td><img src="image" alt="Structure 6e" /></td>
<td>95:5</td>
<td>84</td>
</tr>
<tr>
<td>6</td>
<td><img src="image" alt="Structure 5f" /></td>
<td><img src="image" alt="Structure 6f" /></td>
<td>98:2</td>
<td>89</td>
</tr>
<tr>
<td>7</td>
<td><img src="image" alt="Structure 5g" /></td>
<td><img src="image" alt="Structure 6g" /></td>
<td>–</td>
<td>0</td>
</tr>
<tr>
<td>8</td>
<td><img src="image" alt="Structure 5h" /></td>
<td><img src="image" alt="Structure 6h" /></td>
<td>86:14</td>
<td>74</td>
</tr>
<tr>
<td>9</td>
<td><img src="image" alt="Structure 5i" /></td>
<td><img src="image" alt="Structure 6i" /></td>
<td>92:8</td>
<td>75</td>
</tr>
<tr>
<td>10</td>
<td><img src="image" alt="Structure 5j" /></td>
<td><img src="image" alt="Structure 6j" /></td>
<td>96:4</td>
<td>62</td>
</tr>
<tr>
<td>11</td>
<td><img src="image" alt="Structure 5k" /></td>
<td><img src="image" alt="Structure 6k" /></td>
<td>92:8</td>
<td>72</td>
</tr>
<tr>
<td>12</td>
<td><img src="image" alt="Structure 5l" /></td>
<td><img src="image" alt="Structure 6l" /></td>
<td>96:4</td>
<td>64</td>
</tr>
</tbody>
</table>
Table 1 (continued)

<table>
<thead>
<tr>
<th>Entry</th>
<th>5</th>
<th>6</th>
<th>Ratio*</th>
<th>Yield (%)^b</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td><img src="5m" alt="Image" /></td>
<td><img src="6m" alt="Image" /></td>
<td>82:18</td>
<td>54</td>
</tr>
<tr>
<td>14</td>
<td><img src="5n" alt="Image" /></td>
<td><img src="6n" alt="Image" /></td>
<td>91:7</td>
<td>52</td>
</tr>
<tr>
<td>15</td>
<td><img src="5o" alt="Image" /></td>
<td><img src="6o" alt="Image" /></td>
<td>–</td>
<td>0</td>
</tr>
<tr>
<td>16</td>
<td><img src="5p" alt="Image" /></td>
<td><img src="6p" alt="Image" /></td>
<td>90:10</td>
<td>64</td>
</tr>
<tr>
<td>17</td>
<td><img src="5q" alt="Image" /></td>
<td><img src="6q" alt="Image" /></td>
<td>100:0</td>
<td>54</td>
</tr>
</tbody>
</table>

* Ratio determined by 1H NMR analysis.
^b Yield refers to isolated yield.

Scheme 2 Key NOE enhancements of (2R*,4S*,6S*)-ethyl 4-(tosyl-\(\text{oxy}\))-6-(4-(trifluoromethyl)phenyl)tetrahydro-2H-pyran-2-carboxylate (6f).

A mechanism proposed for the diastereoselectivity of the reaction involves p-TSA protonating the carbonyl group of the ester, leading to formation of oxocarbenium ion B, which, after Prins cyclization, forms tetrahydropyranyl cation C (Scheme 3). The tosyl nucleophile attacks carbocation C equatorially, to give 6 as the major product and 7 as the minor product. This might be due to the lower steric repulsion between the C-2H and C-4H hydrogens compared with intermediate E, where there is a strong steric repulsion between the C-2H hydrogen and the C-4 tosyl group.

This methodology was further extended to the synthesis of 4-iodotetrahydropyrans (Scheme 4). Thus, the reaction of 4-tosyl tetrahydropyrans 6a, 6c, and 6e with cerium(III) chloride heptahydrate and sodium iodide in acetonitrile at 85 °C gave the corresponding 4-iodotetrahydropyrans 8a, 8c, and 8e in moderate yields. 2,4-Disubstituted tosyltetrahydropyran 6a gave a single diastereomer 8a (55%); whereas 2,4,6-trisubstituted tosyltetrahydropyrans 6c (58%) and 6e (55%) gave inseparable mixture of diastereomers 8c and 8e with a ratio of 65:35 and 67:33, respectively.
Similarly, the tosyl group of the 4-tosyl tetrahydropyran 6a, 6c, and 6p can be reduced by sodium borohydride in dimethylsulfoxide at 85 °C to give 9a, 9c, and 9p in 53, 68, and 70% yields, respectively (Scheme 5).

100 °C, provided the corresponding azido compounds 10c and 10h in 66 and 60% yields, respectively, with inversion of configuration at C-4. The configuration of the compounds was determined by NOE analysis of compound 10c. It is noteworthy that the reaction gave only a single diastereomer.

In conclusion, a methodology for the stereoselective synthesis of tosyl substituted tetrahydropyrans through Prins cyclization reaction of acryloyl enol ethers has been developed. Good yields are achieved with high diastereoselectivity. This methodology will be useful for the synthesis of other substituted pyran rings such as 4-iodotetrahydropyrans and 2,6-disubstituted tetrahydropyrans by substitution or reduction of the tosyl functionality, respectively. The tosyl group can also be replaced by an azido group to prepare 4-azidotetrahydropyrans with inversion of configuration at the 4-position.
All the reagents were of reagent grade (AR grade) and were used as purchased without further purification. Silica gel (60–120 mesh size) was used for column chromatography. Reactions were monitored by TLC on silica gel GF254 (0.25 mm). Melting points were determined with a Büchi B-540 melting point apparatus. IR spectra were recorded with a Fourier transform infrared (FTIR) spectrometer either as a neat liquid or as KBr pellets. NMR spectra were obtained with 400 MHz (^1H, 400 MHz and ^13C, 100 MHz) and 600 MHz (^1H, 600 MHz and ^13C, 150 MHz) instruments using CDCl3 as solvent and tetramethylsilane as internal standard. Chemical shifts (δ) are reported in parts per million (ppm) and coupling constants (J) are given in Hz. High-resolution mass spectra (HRMS) were measured with a Q-TOF mass analyzer.

**Synthesis of Starting Materials**

The homoallyl acryloyl ethers were synthesized by following the reported procedure and the structures and purities of known compounds 5a–q were confirmed by comparison of their spectroscopic data (^1H NMR and ^13C NMR) with reported data. 11b

**Synthesis of 4-Tosyloxyl Tetrahydropyrans; Typical Procedure**

To (E)-ethyl 3-(but-3-en-1-yloxy) acrylate (340 mg, 0.5 mmol) in dichloromethane (3 mL) was added p-toluenesulfonic acid monohydrate (408 mg, 0.6 mmol). The reaction mixture was heated to reflux for 8 h and the progress of the reaction was monitored by TLC (EtOAc/hexane, 1:4). Upon completion, the reaction was quenched with aq NaHCO3, extracted (EtOAc), washed with brine, dried (Na2SO4), filtered, and evaporated under reduced pressure. The crude product was purified by column chromatography over silica gel, eluting with EtOAc/hexane to give ethyl 2-((2R,4S*)-4-(tosyloxyl)tetrahydro-2H-pyran-2-yl)acetate (6a) in 68% yield.

**Ethyl 2-((2R,4S*)-4-(tosyloxyl)tetrahydro-2H-pyran-2-yl)acetate (6a, Diastereomeric Mixture, 93:7)**

Yield: 112 mg (68%); pale-yellow gum.

^1H NMR (600 MHz, CDCl3): δ = 1.24 (t, J = 7.2 Hz, 3 H), 1.46–1.52 (m, 1 H), 1.67–1.75 (m, 2 H), 1.84–1.88 (m, 1 H), 1.97–2.00 (m, 1 H), 2.36 (dd, J = 15.6, 5.4 Hz, 1 H), 2.45 (s, 3 H), 2.52 (dd, J = 15.6, 8.4 Hz, 1 H), 3.36 (dd, J = 12.0, 1.2 Hz, 1 H), 3.69–3.75 (m, 1 H), 3.96 (dd, J = 12.0, 4.2 Hz, 1 H), 4.13 (q, J = 7.2 Hz, 2 H), 4.56–4.62 (m, 1 H), 7.35 (d, J = 7.8 Hz, 2 H), 7.79 (d, J = 7.8 Hz, 2 H).

^13C NMR (150 MHz, CDCl3): δ = 14.3, 21.8, 32.6, 38.1, 41.1, 60.9, 65.6, 72.6, 77.9, 127.8, 130.1, 134.5, 145.0, 170.7.

IR (KBr, neat): 3419, 1593 cm–1.


**Ethyl 2-((2R,4R*,6S*)-6-(3-Bromophenyl)-4-(tosyloxyl)tetrahydro-2H-pyran-2-yl)acetate (6c, Diastereomeric Mixture, 99:1)**

Yield: 173 mg (79%); pale-yellow gum.

^1H NMR (600 MHz, CDCl3): δ = 1.22 (t, J = 7.2 Hz, 3 H), 1.52–1.59 (m, 1 H), 1.62–1.68 (m, 1 H), 2.06–2.09 (m, 1 H), 2.20–2.23 (m, 1 H), 2.45 (s, 3 H), 2.46 (dd, J = 15.6, 5.4 Hz, 1 H), 2.63 (dd, J = 15.6, 7.2 Hz, 1 H), 3.92–3.94 (m, 1 H), 4.11 (q, J = 7.2 Hz, 2 H), 3.35 (dd, J = 11.4, 1.8 Hz, 1 H), 4.75–4.79 (m, 1 H), 7.20 (d, J = 8.4 Hz, 2 H), 7.28 (d, J = 8.4 Hz, 2 H), 7.35 (d, J = 8.4 Hz, 2 H), 7.80 (d, J = 8.4 Hz, 2 H).

^13C NMR (150 MHz, CDCl3): δ = 143.2, 38.6, 38.7, 40.1, 60.9, 72.4, 76.5, 77.6, 72.3, 127.8, 128.7, 130.1, 133.7, 134.3, 139.4, 145.1, 170.6.

IR (KBr, neat): 2937, 2854, 1738, 1599, 1494, 1189, 1090, 956, 815, 757, 667, 555 cm–1.


**Ethyl 2-((2R,4R*,6S*)-6-(4-Fluorophenyl)-4-(tosyloxyl)tetrahydro-2H-pyran-2-yl)acetate (6d, Diastereomeric Mixture, 95:5)**

Yield: 160 mg (76%); pale-yellow gum.

^1H NMR (600 MHz, CDCl3): δ = 1.22 (t, J = 7.2 Hz, 3 H), 1.53–1.56 (m, 1 H), 1.65–1.71 (m, 1 H), 2.05–2.09 (m, 1 H), 2.21–2.24 (m, 1 H), 2.45 (dd, J = 15.6, 5.4 Hz, 1 H), 2.46 (s, 3 H), 2.64 (dd, J = 15.6, 7.2 Hz, 1 H), 3.91–3.95 (m, 1 H), 4.12 (q, J = 7.2 Hz, 2 H), 4.35 (dd, J = 11.4, 1.8 Hz, 1 H), 4.74–4.80 (m, 1 H), 7.00 (t, J = 8.4 Hz, 2 H), 7.22–7.25 (m, 2 H), 7.35 (d, J = 8.4 Hz, 2 H), 7.80 (d, J = 8.4 Hz, 2 H).

^13C NMR (150 MHz, CDCl3): δ = 14.4, 21.9, 37.6, 39.7, 40.1, 60.9, 72.4, 76.6, 77.8, 115.4 (d, J = 19.5 Hz), 127.6 (d, J = 7.5 Hz, 2 H), 127.9, 130.1, 134.4, 136.7, 145.1, 162.5 (d, J = 246.0 Hz), 170.6.

IR (KBr, neat): 2928, 1733, 1599, 1367, 1176, 1085, 768, 668, 551 cm–1.

Ethyl 2-((2R*,4R*,6S*)-4-(Tosyloxy)-6-(4-(trifluoromethyl)phenyl)-tetrahydro-2H-pyran-2-yl)acetate (6f, Diastereomeric Mixture, 98:2)

Yield: 210 mg (89%); white solid; mp 120–122 °C.

1H NMR (600 MHz, CDCl3): δ = 1.23 (t, J = 7.2 Hz, 3 H), 1.55–1.61 (m, 1 H), 1.62–1.69 (m, 1 H), 2.07–2.10 (m, 1 H), 2.25–2.29 (m, 1 H), 2.46 (s, 3 H), 2.47 (dd, J = 15.6, 5.4 Hz, 1 H), 2.65 (dd, J = 15.6, 7.8 Hz, 1 H), 3.94–3.68 (m, 1 H), 4.12 (q, J = 7.2 Hz, 2 H), 4.44 (dd, J = 11.4, 1.8 Hz, 1 H), 4.77–4.82 (m, 1 H), 7.35 (d, J = 8.4 Hz, 2 H), 7.39 (d, J = 8.4 Hz, 2 H), 7.57 (d, J = 8.4 Hz, 2 H), 7.75 (d, J = 8.4 Hz, 2 H).

13C NMR (150 MHz, CDCl3): δ = 14.4, 21.9, 37.7, 39.6, 41.1, 60.8, 72.3, 77.0, 78.2, 126.0, 127.8, 129.3, 130.1, 134.4, 137.8, 137.9, 145.0, 170.7.

IR (KBr, neat): 2932, 2865, 1734, 1621, 1594, 1371, 1162, 1012, 842, 754, 672, 5556 cm–1.


Ethyl 2-((2R*,4R*,6S*)-6-(2-Chlorophenyl)-4-(tosyloxy)tetrahydro-2H-pyran-2-yl)acetate (6k, Diastereomeric Mixture; 92:8)

Yield: 326 mg (72%); yellow oil.

1H NMR (600 MHz, CDCl3): δ = 1.21 (t, J = 7.2 Hz, 3 H), 1.43–1.50 (m, 1 H), 1.56–1.62 (m, 1 H), 2.11–2.14 (m, 1 H), 2.23–2.26 (m, 1 H), 2.43 (s, 3 H), 2.48 (dd, J = 15.6, 5.4 Hz, 1 H), 2.65 (dd, J = 15.6, 7.2 Hz, 1 H), 3.96–4.00 (m, 1 H), 4.10 (q, J = 7.2 Hz, 2 H), 4.67 (dd, J = 12.0, 1.6 Hz, 1 H), 4.76–4.81 (m, 1 H), 7.16–7.18 (m, 1 H), 7.22–7.27 (m, 2 H), 7.34 (d, J = 7.8 Hz, 2 H), 7.46 (d, J = 7.8 Hz, 1 H), 7.80 (d, J = 7.8 Hz, 2 H).

13C NMR (150 MHz, CDCl3): δ = 14.4, 14.5, 21.6, 21.9, 35.6, 37.6, 37.7, 39.7, 41.1, 41.3, 60.7, 60.8, 68.3, 68.8, 71.7, 71.9, 76.9, 78.1, 127.8 (4C), 127.9 (4C), 130.2, 134.5, 145.0, 170.9.

IR (KBr, neat): 2926, 2853, 1738, 1, 1598, 1474, 1362, 1189, 1007, 814, 793 cm–1.


Yield: 305 mg (64%); colorless oil.

1H NMR (600 MHz, CDCl3): δ = 1.23 (t, J = 7.2 Hz, 3 H), 1.50–1.70 (m, 2 H), 1.98–2.10 (m, 1 H), 2.24–2.27 (m, 1 H), 2.33–2.36 (m, 1 H), 2.46 (s, 3 H), 2.63–2.67 (m, 1 H), 3.90 (s, 3 H), 4.07–4.13 (m, 3 H), 4.41 (d, J = 10.8 Hz, 2 H), 4.70–4.80 (m, 1 H), 7.34 (t, J = 16.2 Hz, 4 H), 7.80 (d, J = 9.0 Hz, 2 H), 8.00 (d, J = 8.4 Hz, 2 H).

13C NMR (150 MHz, CDCl3): δ = 14.3, 14.4, 21.9, 37.4, 39.7, 41.0, 61.0, 72.1, 76.7, 77.1, 125.6, 125.8, 127.8, 129.8, 130.1, 143.3, 145.1, 145.2, 167.0, 170.6.

IR (KBr, neat): 2938, 2861, 1734, 1626, 1594, 1372, 1161, 1012, 842, 756, 672, 559 cm–1.

Ethyl 2-((2R*,4R*,6S*)-6-Isopropyl-4-(tosyloxy)tetrahydro-2H-pyran-2-yl)acetate (6n, Diastereomeric Mixture; 93:7)

Yield: 207 mg (52%); orange gum.

1H NMR (400 MHz, CDCl3); δ = 0.83 (d, J = 6.6 Hz, 3 H), 0.85 (d, J = 6.6 Hz, 3 H), 1.10–1.14 (m, 1 H), 1.23 (t, J = 7.2 Hz, 3 H), 1.34–1.44 (m, 2 H), 1.45–1.48 (m, 1 H), 1.68–1.72 (m, 2 H), 1.88–1.96 (m, 2 H), 2.35 (dd, J = 15.0, 4.8 Hz, 1 H), 2.46 (s, 3 H), 2.51 (dd, J = 15.0, 8.4 Hz, 1 H), 3.31–3.35 (m, 1 H), 3.68–3.73 (m, 1 H), 4.08–4.16 (m, 2 H), 4.57–4.66 (m, 1 H), 7.35 (d, J = 7.8 Hz, 2 H), 7.79 (d, J = 7.8 Hz, 2 H).

13C NMR (150 MHz, CDCl3); δ = 14.4, 21.9, 22.1, 23.3, 24.6, 37.8, 38.6, 41.3, 44.8, 60.8, 72.1, 73.8, 78.3, 127.8, 130.1, 134.5, 145.0, 170.9.

IR (KBr, neat); 2955, 2869, 1738, 1598, 1367, 1190, 1097, 935, 844, 793, 669, 579 cm⁻¹.


Ethyl 2-((2R*,4R*,6S*)-6-(Naphthalen-1-yl)-4-(tosyloxy)tetrahydro-2H-pyran-2-yl)acetate (6p, Diastereomeric Mixture; 95:5)

Yield: 330 mg (64%); pale-yellow oil.

1H NMR (400 MHz, CDCl3); δ = 1.21 (t, J = 7.0 Hz, 3 H), 1.56–1.66 (m, 1 H), 1.75–1.84 (m, 1 H), 2.09–2.15 (m, 1 H), 2.28–2.33 (m, 1 H), 2.42 (s, 3 H), 2.48 (dd, J = 15.6, 5.4 Hz, 1 H), 2.68 (dd, J = 15.6, 7.4 Hz, 1 H), 3.96–4.03 (m, 1 H), 4.11 (q, J = 7.0 Hz, 2 H), 4.52 (d, J = 10.2 Hz, 1 H), 4.79–4.87 (m, 1 H), 7.31–7.33 (m, 2 H), 7.36–7.39 (m, 1 H), 7.43–7.45 (m, 2 H), 7.71 (s, 1 H), 7.77–7.82 (m, 5 H).

13C NMR (100 MHz, CDCl3); δ = 14.3 (2C), 21.8, 37.6, 39.6, 41.0, 60.8, 72.4, 78.0, 124.1, 124.7, 126.1, 127.8, 128.1, 128.3, 130.1, 133.1, 133.3, 134.3, 138.2, 145.0, 170.7.

IR (KBr, neat); 2917, 2845, 1732, 1593, 1357, 1188, 1060, 955, 816, 744, 660, 552 cm⁻¹.


Ethyl 2-((2R*,4S*,6R*)-6-Benzyl-4-(tosyloxy)tetrahydro-2H-pyran-2-yl)acetate (6q, Diastereomeric Mixture; 100:0)

Yield: 233 mg (54%); pale-yellow oil.

1H NMR (400 MHz, CDCl3); δ = 1.22–1.27 (m, 3 H), 1.65–1.74 (m, 1 H), 1.97–2.22 (m, 2 H), 2.44–2.55 (m, 2 H), 2.61–2.70 (m, 1 H), 3.95–4.00 (m, 2 H, minor), 4.14 (q, J = 7.0 Hz, 2 H), 4.34–4.38 (m, 2 H, major), 4.39–4.47 (m, 1 H, minor), 4.88–4.92 (m, 1 H, major), 7.23 (d, J = 8.5 Hz, 2 H), 7.30 (d, J = 8.5 Hz, 2 H).

13C NMR (100 MHz, CDCl3); δ = 14.4, 14.5, 20.4, 28.9, 39.9, 40.8, 40.9, 42.3, 44.3, 46.7, 60.8, 60.9, 71.2, 75.1, 75.6, 80.0, 127.3, 127.4, 128.6, 128.7, 133.4, 133.6, 139.6, 140.3, 170.7, 170.9.

IR (KBr, neat); 3018, 1734, 1400, 1192, 1074, 819, 653, 552 cm⁻¹.


Ethyl 2-((2S*,4S*,6S*)-6-(3-Bromophenyl)-4-iodotetrahydro-2H-pyran-2-yl)acetate (8a, Diastereomeric Mixture; 65:35)

Yield: 146 mg (58%); yellow gum.

1H NMR (400 MHz, CDCl3); δ = 1.22–1.27 (m, 3 H), 1.65–1.74 (m, 1 H), 1.97–2.22 (m, 2 H), 2.44–2.55 (m, 2 H), 2.61–2.70 (m, 1 H), 3.95–4.00 (m, 2 H, minor), 4.14 (q, J = 7.0 Hz, 2 H), 4.34–4.38 (m, 2 H, major), 4.39–4.47 (m, 1 H, minor), 4.88–4.92 (m, 1 H, major), 7.23 (d, J = 8.5 Hz, 2 H), 7.30 (d, J = 8.5 Hz, 2 H).

13C NMR (100 MHz, CDCl3); δ = 14.4, 14.5, 20.4, 28.9, 39.9, 40.8, 40.9, 42.3, 44.3, 46.7, 60.8, 60.9, 71.2, 75.1, 75.6, 80.0, 127.3, 127.4, 128.6, 128.7, 133.4, 133.6, 139.6, 140.3, 170.7, 170.9.

IR (KBr, neat); 3018, 1734, 1400, 1192, 1074, 819, 653, 552 cm⁻¹.


Synthesis of Ethyl 2-((Tetrahydro-2H-pyran-2-yl)acetates; Typical Procedure

To a stirred solution of 6a (200 mg, 0.58 mmol) in DMSO (0.2 M) was slowly added NaBr₄ (67 mg, 1.75 mmol). The reaction mixture was stirred at 85 °C for 6 h and progress of the reaction was monitored by TLC. After completion, the reaction was quenched with brine and extracted (EtOAc, 2 × 10 mL). The combined organic phases were dried over Na₂SO₄ filtered and concentrated under reduced pressure. The residue was purified by column chromatography, eluting with EtOAc/hexane, 5:95 to give 9a.
Ethyl 2-((2R,6S)-6-(4-Chlorophenyl)tetrahydro-2H-pyran-2-yl)acetate (9a)
Yield: 0.56 (53%); colorless liquid.

**1H NMR (400 MHz, CDCl₃):** δ = 1.26 (t, J = 7.2 Hz, 3 H), 1.28–1.31 (m, 2 H), 1.47–1.56 (m, 3 H), 1.62–1.66 (m, 1 H), 1.83–1.84 (m, 1 H), 2.38 (dd, J = 15.0, 50.0 Hz, 1 H), 2.50 (dd, J = 15.0, 80.0 Hz, 1 H), 3.42–3.49 (m, 1 H), 3.71–3.78 (m, 1 H), 3.96 (dd, J = 1.0, 20.0 Hz, 1 H), 4.15 (q, J = 7.2 Hz, 2 H).

**13C NMR (100 MHz, CDCl₃):** δ = 73.6, 74.1, 125.9, 129.2, 137.4, 139.1, 171.0.

**IR (KBr, neat):** 2938, 2859, 1736, 1400, 1249, 1188, 1087, 831 cm⁻¹.

**HRMS (ESI):** m/z [M + H]⁺ calcd for C₅H₁₀ClO₃: 283.1095; found: 283.1168.

Yield: 92 mg (66%); pale-yellow oil.

**1H NMR (600 MHz, CDCl₃):** δ = 1.27 (t, J = 7.2 Hz, 3 H), 1.69–1.72 (m, 2 H), 1.91–1.97 (m, 2 H), 2.50 (dd, J = 15.2, 60.0 Hz, 1 H), 2.64 (dd, J = 15.0, 7.2 Hz, 1 H), 4.15–4.20 (m, 3 H), 4.30–4.35 (m, 1 H), 4.74 (d, J = 11.2 Hz, 1 H), 7.27 (d, J = 8.4 Hz, 2 H), 7.31 (d, J = 8.4 Hz, 2 H).

**13C NMR (150 MHz, CDCl₃):** δ = 14.4, 34.5, 37.1, 41.3, 55.9, 60.8, 69.6, 73.6, 127.3, 128.7, 133.4, 140.6, 170.9.

**IR (KBr, neat):** 2928, 2821, 2105, 1736, 1600, 1400, 1273, 128.7, 133.4, 140.6, 170.9.

**HRMS (ESI):** m/z [M + H]⁺ calcd for C₁₀H₁₇ClN₃O₃: 324.1109; found: 324.1156.

Ethyl 2-((2S*,4R*,6R*)-4-Azido-6-(p-Tolyl)tetrahydro-2H-pyran-2-yl)acetate (10b)
Yield: 110 mg (40%); pale-yellow oil.

**1H NMR (400 MHz, CDCl₃):** δ = 1.24 (t, J = 7.0 Hz, 3 H), 1.62–1.70 (m, 2 H), 1.72–1.79 (m, 1 H), 1.87–1.97 (m, 2 H), 2.32 (s, 3 H), 2.46 (dd, J = 15.0, 60.0 Hz, 1 H), 2.63 (dd, J = 15.0, 7.0 Hz, 1 H), 4.11–4.18 (m, 3 H), 4.26–4.33 (m, 1 H), 4.71 (d, J = 10.0 Hz, 2 H), 7.13 (d, J = 8.0 Hz, 2 H), 7.21 (d, J = 8.0 Hz, 2 H).

**13C NMR (100 MHz, CDCl₃):** δ = 14.0, 21.3, 34.6, 36.9, 41.4, 56.1, 60.7, 69.6, 74.1, 125.9, 129.2, 137.4, 139.1, 171.0.

**IR (KBr, neat):** 2929, 2823, 2103, 1737, 1620, 1400, 1245, 1187, 1065, 1028, 809 cm⁻¹.


**Funding Information**
This work is supported by the Department of Science and Technology (DST), New Delhi (Grant No. EMR/2016/006411), and CoE, MHRD, Government of India.

**Acknowledgment**
S.S. gratefully acknowledges the Indian Institute of Technology Guwahati for a Fellowship. The authors are also grateful to the Central Instrument Facility (CIF) of IIT Guwahati for use of the NMR facility.

**Supporting Information**
Supporting information for this article is available online at https://doi.org/10.1055/s-0037-1611679.

**References**


